OMERS ADMINISTRATION Corp Takes $864,000 Position in Sarepta Therapeutics, Inc. $SRPT

Key Points

• OMERS Administration Corp. acquired 48,054 Sarepta Therapeutics shares worth approximately $864,000 in the second quarter. Institutional investors and hedge funds collectively own 86.68% of SRPT.
• Sarepta reported quarterly EPS of $0.64, exceeding the $0.22 analyst consensus, while revenue of $401.25 million also topped estimates. However, revenue declined 34.3% year over year and the company posted a negative net margin.
• Analyst sentiment remains mixed, with nine Buy, six Hold, and five Sell ratings. The stock has a consensus rating of Hold and an average price target of $25.06, versus a recent price of $21.59.

OMERS ADMINISTRATION Corp acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 48,054 shares of the biotechnology company's stock, valued at approximately $864,000.

Other hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Sarepta Therapeutics in the second quarter worth about $341,339,000. AQR Capital Management LLC raised its position in shares of Sarepta Therapeutics by 454.6% in the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company's stock valued at $167,781,000 after purchasing an additional 6,390,860 shares during the last quarter. First Trust Advisors LP raised its position in shares of Sarepta Therapeutics by 107.6% in the 1st quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company's stock valued at $89,995,000 after purchasing an additional 2,143,211 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Sarepta Therapeutics by 9.2% in the 4th quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company's stock valued at $254,167,000 after purchasing an additional 993,283 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $17,494,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $21.59 on Friday. The business's 50 day moving average price is $17.66 and its 200 day moving average price is $18.30. The firm has a market cap of $2.28 billion, a P/E ratio of -7.44, a P/E/G ratio of 0.29 and a beta of 0.23. Sarepta Therapeutics, Inc. has a 52 week low of $14.68 and a 52 week high of $25.32. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $0.42. The company had revenue of $401.25 million during the quarter, compared to analyst estimates of $366.39 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. Sarepta Therapeutics's revenue for the quarter was down 34.3% compared to the same quarter last year. During the same period last year, the firm posted $2.02 EPS. On average, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 3.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on SRPT. Wolfe Research raised shares of Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a research report on Thursday, July 9th. Weiss Ratings cut shares of Sarepta Therapeutics from a "sell (d)" rating to a "sell (e+)" rating in a report on Wednesday, August 19th. Wall Street Zen downgraded shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Piper Sandler dropped their price objective on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating on the stock in a report on Thursday, July 9th. Finally, HC Wainwright reissued a "buy" rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $25.06.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source